ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES

被引：0
|
作者：
Cerchione, C. [1 ]
Alfinito, F. [2 ]
Soriente, I. [3 ]
D'Arco, A. M. [3 ]
Danise, P. [3 ]
Cerciello, G. [3 ]
Musuraca, G. [1 ]
Lucchesi, A. [1 ]
Di Battista, V. [1 ]
Cangini, D. [1 ]
Giannini, M. B. [1 ]
Ronconi, S. [1 ]
Ceccolini, M. [1 ]
Pane, F. [2 ]
Martinelli, G. [1 ]
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, Italy
[2] AOU Federico II, Hematol, Naples, Italy
[3] Osped Pagani, Hematol, Pagani, Italy
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P001
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [21] Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
    Kosmider, Olivier
    Passet, Marie
    Santini, Valeria
    Platzbecker, Uwe
    Andrieu, Valerie
    Zini, Gina
    Beyne-Rauzy, Odile
    Guerci, Agnes
    Masala, Erico
    Balleari, Enrico
    Bulycheva, Ekaterina
    Dreyfus, Francois
    Fenaux, Pierre
    Fontenay, Michaela
    Park, Sophie
    HAEMATOLOGICA, 2016, 101 (07) : 280 - 283
  • [22] Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
    Smith, Sheila Weiss
    Sato, Masayo
    Gore, Steven D.
    Baer, Maria R.
    Ke, Xuehua
    McNally, Diane
    Davidoff, Amy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (01): : 15 - 20
  • [23] Erythropoiesis stimulating agents and other growth factors in low-risk MDS
    Hellstrom-Lindberg, Eva p
    van de Loosdrecht, Arjan
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) : 401 - 410
  • [24] Patterns of care in patients with chemotherapy receiving erythropoiesis stimulating agents (ESAs)
    Naeim, Arash
    Friedman, Lyssa
    Elkin, Eric
    Adams, Sara
    Viswanathan, Hema
    Kallich, Joel
    Glaspy, John
    BLOOD, 2007, 110 (11) : 294A - 294A
  • [25] Treatment of low-risk myelodysplastic syndromes
    Santini, Valeria
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 462 - 469
  • [26] Validation of Predictive Models for Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndromes
    Gowanlock, Zachary
    Sriram, Swetha
    Martin, Alison
    Lazo-Langner, Alejandro
    BLOOD, 2015, 126 (23)
  • [27] A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes
    Madanat, Yazan F.
    Dezern, Amy E.
    LANCET HAEMATOLOGY, 2024, 11 (09): : e630 - e631
  • [28] Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs).
    Sibon, David
    Cannas, Giovanna
    Barraco, Fiorenza
    Prebet, Thomas
    Vey, Norbert
    Banos, Anne
    Besson, Caroline
    Corm, Selim
    Blanc, Michel
    Slama, Borhane
    Perrier, Herve
    Fenaux, Pierre
    Wattel, Eric
    BLOOD, 2010, 116 (21) : 1632 - 1632
  • [29] rHuEpo treatment in low-risk myelodysplastic syndromes
    Grossi, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 574 - 574
  • [30] Erythropoietin for the anemia of low-risk myelodysplastic syndromes
    Fenaux, P
    Ades, L
    BLOOD, 2005, 106 (03) : 768 - 769
12345